The financial markets responded immediately, with BioNTech shares declining as much as 5% in pre-market trading. This partnership has historically formed the cornerstone of BioNTech's commercial ...

Five years after their celebrated collaboration on a COVID-19 vaccine, Pfizer has initiated a significant divestment, selling ...

The strategic partnership that yielded one of history's most successful vaccines reached a turning point this week. Pfizer ...

Pfizer sell 508M stake in BioNTech through an overnight block trade, marking its exit from the COVID-19 vaccine partner's equity.

A BioNTech spokesperson downplayed the news, insisting that the two companies remain “close” and have a “strong collaboration ...

The Metsera buyout brings multiple obesity and cardiometabolic drug candidates into Pfizer’s pipeline, including a GLP-1 ...

Pfizer Inc said on Thursday it sold a part of its stake in German drugmaker BioNTech SE , more than five years after both ...

A BioNTech spokesperson told Reuters that the two companies continue to have a “close and strong collaboration.” ...

BioNTech (BNTX) stock slips as Pfizer (PFE) plans to sell its remaining stake in the COVID-19 vaccine developer in a ...

Strong financial position with cash, cash equivalents and marketable securities of $93.7M Moderna litigation U.S. trial scheduled for March ...

BioNTech said on Thursday that its collaboration with Pfizer has not changed, when asked to comment on a report that Pfizer ...

--Pfizer is trying to sell its stake in BioNTech SE, Bloomberg reported, citing people familiar with the matter. --Pfizer is offering 4.55 million American depositary receipts for $108 to $111.70 a ...